NF1 and melanoma: Of the 56 tumours with Class II mutations, six (10.7%), all classified as melanoma, had additional MAPK pathway mutations, including BRAFK601E, BRAFG469A, NRASQ61K, NRASG12D, HRASQ61K, and NF1W1559∗ (NF1 was not included in the NGS panel for 16 tumours).